Karius

Karius focuses on medical diagnostics for infectious diseases, offering the Karius Test, a liquid biopsy that detects over 1,000 pathogens from a single blood sample. This non-invasive test is quick and helps clinicians treat hospitalized patients by reducing the need for multiple invasive tests that can delay treatment. The Karius Test utilizes advanced genomics and artificial intelligence to identify microbial cell-free DNA (mcfDNA) in the bloodstream, providing insights into the pathogens responsible for infections. Karius differentiates itself from competitors by offering a faster, non-invasive alternative to traditional diagnostic methods, which can save lives and lower healthcare costs. The company's goal is to enhance infectious disease diagnostics through continuous learning and improvement of their machine learning algorithms and genomic databases.